GlobalData

The respiratory complications market is set to grow from $21.8 billion in 2015 to $30.2 billion by 2022,

The company's latest report states that, despite a small late-stage pipeline, the space will see a

Yasser Mushtaq, Senior Analyst for GBI Research, explains: "There are few drugs that generate substa

Several recently approved drugs are expected to unlock a substantial degree of commercial potential w

The most notable of these are Uptravi (selexipag) and Opsumit (macitentan), both marketed by Actelio

Mushtaq continues: "Pfizer is expected to maintain its position as market leader throughout the entire fo

"Smaller biopharmaceutical firms, such as Actelion, Novavax, and United Therapeutics, also feature pr